Table 3 In-hospital management of ACS patients with diabetes/possible diabetes
| Â | STEMI | NSTE-ACS | ||||
|---|---|---|---|---|---|---|
Diabetes/possible diabetes (N = 14,650) | No diabetes (N = 25,143) | p value | Diabetes/possible diabetes (N = 9230) | No diabetes (N = 14,427) | p value | |
DAPT, % (n/N) | 95.4 (13,911/14,577) | 95.5 (23,915/25,037) | 0.686 | 89.4 (8130/9098) | 90.0 (12,827/14,250) | 0.108 |
 Aspirin, % (n/N) | 96.3 (14,032/14,579) | 96.5 (24,163/25,038) | 0.184 | 93.1 (8469/9100) | 93.6 (13,343/14,253) | 0.099 |
 P2Y12 inhibitors, % (n/N) | 96.9 (14,194/14,643) | 96.7 (24,295/25,135) | 0.134 | 92.7 (8534/9211) | 92.9 (13,394/14,411) | 0.395 |
GPIIb/IIIa, % (n/N) | 39.8 (5816/14,625) | 38.4 (9651/25,112) | 0.008 | 17.5 (1612/9196) | 17.3 (2494/14,406) | 0.668 |
Anticoagulant, % (n/N) | 79.4 (11,632/14,643) | 79.2 (19,912/25,135) | 0.606 | 68.1 (6273/9211) | 67.1 (9668/14,411) | 0.104 |
 UFH | 5.3 (768/14,623) | 4.5 (1121/25,097) | < 0.001 | 2.0 (185/9171) | 1.9 (271/14,379) | 0.472 |
 LMWH | 73.0 (10,676/14,623) | 73.7 (18,490/25,097) | 0.147 | 62.8 (5760/9171) | 62.4 (8969/14,379) | 0.505 |
 Fondaparinux sodium | 1.3 (186/14,623) | 1.0 (262/25,097) | 0.038 | 2.2 (201/9171) | 1.6 (232/14,379) | 0.001 |
 Other anticoagulants | 1.9 (280/14,623) | 2.0 (512/25,097) | 0.389 | 2.0 (185/9171) | 2.0 (280/14,379) | 0.707 |
Statins, % (n/N) | 94.1(37,382/39,735) | 94.0 (13,748/14,628) | 0.544 | 92.9 (8562/9212) | 93.4 (13,459/14,408) | 0.161 |
Beta-blockers, % (n/N) | 64.3 (2917/4536) | 62.5 (4998/7997) | 0.044 | 67.6 (2046/3028) | 66.4 (3431/5164) | 0.295 |
ACEI/ARB, % (n/N) | 49.8 (6687/13,427) | 48.4 (11,151/23,030) | 0.011 | 54.0 (4643/8606) | 48.8 (6535/13,396) | < 0.001 |
PCI, % (n/N) | 77.1 (11,289/14,650) | 77.5 (19,484/25,143) | < 0.001 | 58.2 (5367/9230) | 61.1 (8810/14,427) | 0.006 |
 Time of PCIa, % (n/N) (h) |  |  | < 0.001 |  |  | 0.006 |
  < 2 | 55.2 (8574/15,526) | 57.4 (5220/9100) |  | 10.0 (734/7341) | 8.9 (388/4383) |  |
  2–11.9 | 10.2 (1577/15,526) | 11.5 (1046/9100) |  | 10.0 (731/7341) | 10.8 (474/4383) |  |
  12–23.9 | 3.2 (493/15,526) | 3.4 (313/9100) |  | 7.8 (572/7341) | 7.2 (314/4383) |  |
  24–71.9 | 9.8 (1524/15,526) | 8.9 (809/9100) |  | 31.2 (2293/7341) | 29.5 (1294/4383) |  |
  ≥ 72 | 21.6 (3358/15,526) | 18.8 (1712/9100) |  | 41.0 (3011/7341) | 43.7 (1913/4383) |  |
 Type of stentsb, % (n/N) |  |  | 0.010 |  |  | 0.088 |
  Drug eluting stent | 98.1 (9827/10,017) | 98.1 (16,825/17,145) |  | 96.9 (4317/4456) | 96.7 (6997/7235) |  |
  Bare metal stent | 1.0 (101/10,017) | 1.2 (213/17,145) |  | 1.8 (82/4456) | 1.6 (113/7235) |  |
  Other | 0.9 (89/10,017) | 0.6 (107/17,145) |  | 1.3 (57/4456) | 1.7 (125/7235) |  |
CABG, % (n/N) | 0.5 (46/10,121) | 0.5 (94/17,328) | 0.324 | 0.7 (33/4670) | 0.7 (51/7583) | 0.824 |
Length of stay, median (IQR), day | 10.0 (7.0–13.0) | 10.0 (7.0–13.0) | < 0.001 | 10.0 (7.0–13.0) | 9.0 (7.0–12.0) | < 0.001 |